focus -WSS

focus

author：Wikipedia 2025-09-27 23:32:58 - browse：491

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Biden report: The neurospychology of memory and aging

WSS

Democrats decry new health bill for going easy on private equity

CDC Director Mandy Cohen on transparency, trust, and health

PhRMA lawsuit over Medicare drug price negotiation tossed

New lawsuit accuses health insurer Cigna of denying claims in bulk

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

focus

focus

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

For Medicare Advantage, Democrats want stronger protections around AI

BioMarin wins approval for gene therapy to treat hemophilia A

Gilead might be held responsible for not developing a drug

Cancer drug shortages should be causing more outrage

PhRMA lawsuit over Medicare drug price negotiation tossed

Medical records are filled with copy

How doctors’ personal politics affect patients

Guidelines to prevent youth baseball injuries need more muscle

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

hotspot

CDC Director Mandy Cohen on transparency, trust, and health

Senate panel puts off hardest PBM reforms for another day

Robert F. Kennedy is pitching centrism on health, even on abortion

Biogen Alzheimer’s drug launch off to slow start

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Vaccine advisory panel ACIP left half staffed by HHS

hotspot

explore

hotspot

explore